Insulet Corp (PODD) P/FCF 29.6 | Overview

Search global stocks & ETFs...Ctrl K

Learn Mode

Insulet CorpPODD

$165.68

-$4.94 (-2.895%)

8:00 PM

4.18/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

Updates

PODD

Stock Profile

Market Cap

$11.48B

Industry

Health Care

EPS (TTM)

$4.30

P/E (TTM)

37.90

Div & Yield

FCF Payout Ratio

P/S (TTM)

3.96

P/B

7.57

Revenue Growth (TTM)

31.93%

EPS CAGR (3Y)

654.23%

Diluted Shares

70.20M

Ex-Dividend

Next Earnings

08-05

Forward P/E

23.04

Payout Ratio

P/FCF (TTM)

29.60

FCF Yield

3.38%

Earnings Yield

2.64%

Revenue CAGR (3Y)

28.47%

Recommended Metric

Score Card

Explore Scores Tab

4.18

Good

Insulet Corp has grown revenue at 31.93% over the past year, which is strong growth. Also, it has more cash than current liabilities meaning it has enough cash to handle all its debts within the next year, if it wanted to.

Valuation Score

Key Score

5.00

Very Good

Management

3.00

Average

Growth

5.00

Very Good

Profitability

5.00

Very Good

Fin. Health

3.00

Average

Dividends

Analyst

4.00

Good

Financials

Explore Financial Tab ›

Revenue

Earnings

Free Cash Flow

Insider Transactions

Explore Insider Tab ›

Buy Transactions

Sell Transactions

Peers

Select stocks to compare

Price Targets & Ratings

View Analysis

1-year price targets, ending Jun 28, 2027

Current

$165.68

Baseline

High

$420.00

▲

153.50%

Avg

$262.50

▲

58.44%

Low

$166.65

▲

0.59%

Analyst Ratings based on 35 Analysts

Strong Buy

34%

Buy

51%

Hold

14%

Sell

00%

Strong Sell

00%

About

Website

Address

SEC

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts and currently employs 5,400 full-time employees. The company went IPO on 2007-05-15. The company is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. The company also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.Read More

IPO Date

2007-05-15

Industry

Health Care

Total Employees

5,400

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Health Care Equipment & Supplies

GICS Sub

Health Care Equipment

GICS Sector

Health Care

GICS Group

Health Care Equipment & Services

Stock News

View All Updates

GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates